RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Coherus BioSciences Stock

Coherus BioSciences ROE 2024

Coherus BioSciences ROE

1.23

Ticker

CHRS

ISIN

US19249H1032

WKN

A12ETZ

In 2024, Coherus BioSciences's return on equity (ROE) was 1.23, a -42.09% increase from the 2.12 ROE in the previous year.

Coherus BioSciences Aktienanalyse

What does Coherus BioSciences do?

Coherus BioSciences Inc is a pharmaceutical company specializing in the development and marketing of biosimilars. The company was founded in California in 2010 and has since focused on the development of biopharmaceuticals. Coherus BioSciences Inc's history began with the acquisition of the biomanufacturing facility from PDL BioPharma, a company specialized in the development and marketing of therapeutics and biologics. Coherus BioSciences Inc used the facility to build a portfolio of biosimilars. Coherus BioSciences Inc's business model is based on the sale of biosimilars, which offer a cost-effective alternative to expensive biologics. Biosimilars are biopharmaceuticals that are manufactured similarly to already approved biologics, but can be offered at a lower price. Coherus BioSciences Inc specializes in the development and marketing of biosimilars in the fields of oncology, immunology, and neurology. The products that the company currently brings to market or is developing include biosimilar versions of Enbrel, Neulasta, and Humira. Enbrel is a biologic used to treat rheumatoid arthritis, psoriasis, and other inflammatory conditions. Neulasta is a medication used to support white blood cells after chemotherapy, while Humira is a medication used to treat autoimmune diseases such as rheumatoid arthritis, Crohn's disease, and psoriasis. Coherus BioSciences Inc has also launched a collaboration with Novartis to develop a biosimilar version of Lucentis. Lucentis is a biologic used to treat age-related macular degeneration. Overall, Coherus BioSciences Inc has built a portfolio of ten biosimilars and is working to bring more products to market. The company has also conducted several preclinical and clinical studies to demonstrate the efficacy and safety of its biosimilars. Coherus BioSciences Inc is headquartered in Redwood City, California. The company currently employs over 140 employees and has offices in the USA, Europe, and Asia. Overall, Coherus BioSciences Inc has played a groundbreaking role in the development of cost-effective biosimilars. The company specializes in the marketing of biosimilars and offers a range of products in the fields of oncology, immunology, and neurology. Coherus BioSciences Inc has also launched a collaboration with another company to develop a biosimilar version of Lucentis. The company has built a portfolio of ten biosimilars and is constantly expanding its offerings. Coherus BioSciences ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROE Details

Decoding Coherus BioSciences's Return on Equity (ROE)

Coherus BioSciences's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing Coherus BioSciences's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

Coherus BioSciences's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in Coherus BioSciences’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about Coherus BioSciences stock

What is the ROE (Return on Equity) of Coherus BioSciences this year?

The ROE of Coherus BioSciences this year is 1.23 undefined.

How has the Return on Equity (ROE) of Coherus BioSciences developed compared to the previous year?

The ROE of Coherus BioSciences has increased by -42.09% decreased compared to the previous year.

What impact does a high ROE (Return on Equity) have on investors of Coherus BioSciences?

A high ROE indicates that Coherus BioSciences generates good returns on capital and is successful in monetizing its investments. This is a positive indicator for investors.

What impact does a low ROE (Return on Equity) have on investors of Coherus BioSciences?

A low ROE can indicate that Coherus BioSciences is having difficulties monetizing its investments successfully and can be a negative signal for investors.

How does a change in the ROE (Return on Equity) of Coherus BioSciences affect the company?

A change in ROE (Return on Equity) of Coherus BioSciences can be an indicator of the financial performance of the company and demonstrate how successful the company is compared to other companies in the same industry.

How to calculate the ROE (Return on Equity) of Coherus BioSciences?

The ROE (Return on Equity) is calculated by dividing the company's profit by the total equity. The formula is: ROE = Profit / Total equity.

Which factors influence the ROE (Return on Equity) of Coherus BioSciences?

Some factors that can influence Coherus BioSciences's Return on Equity (ROE) include the efficiency in using equity, the profitability of the company, and the financing structure.

What strategic measures can take to improve the ROE (Return on Equity)?

To improve the Return on Equity (ROE), can take measures such as cost savings, increasing revenue, improving efficiency in the use of equity, and making changes in the financing structure. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic actions to improve ROE.

How much dividend does Coherus BioSciences pay?

Over the past 12 months, Coherus BioSciences paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Coherus BioSciences is expected to pay a dividend of 0 USD.

What is the dividend yield of Coherus BioSciences?

The current dividend yield of Coherus BioSciences is .

When does Coherus BioSciences pay dividends?

Coherus BioSciences pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Coherus BioSciences?

Coherus BioSciences paid dividends every year for the past 0 years.

What is the dividend of Coherus BioSciences?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Coherus BioSciences located?

Coherus BioSciences is assigned to the 'Health' sector.

Wann musste ich die Aktien von Coherus BioSciences kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Coherus BioSciences from 8/24/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 8/24/2024.

When did Coherus BioSciences pay the last dividend?

The last dividend was paid out on 8/24/2024.

What was the dividend of Coherus BioSciences in the year 2023?

In the year 2023, Coherus BioSciences distributed 0 USD as dividends.

In which currency does Coherus BioSciences pay out the dividend?

The dividends of Coherus BioSciences are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Coherus BioSciences stock can be added to a savings plan with the following providers: Trade Republic

Andere Kennzahlen von Coherus BioSciences

Our stock analysis for Coherus BioSciences Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Coherus BioSciences Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.